证券日报网讯 1月4日，新华医疗发布公告称，公司第十一届董事会第二十四次会议审议通过《关于制 定"提质增效重回报"行动方案的议案》《关于对全资子公司新华医疗康复产业（西安）有限公司增资的 议案》。 （编辑 王江浩） ...

Core Viewpoint - Xinhua Medical (600587.SH) has made significant progress in the research, production, and sales of rehabilitation equipment through its subsidiary in Xi'an, establishing a solid industrial foundation [1] Group 1: Company Developments - The Xi'an rehabilitation company has achieved good progress in R&D, production, and sales [1] - The company has built a strong industrial foundation based on professional technical accumulation and precise market positioning [1] - To accelerate the R&D, production, and sales of rehabilitation equipment, the company plans to increase its investment in the Xi'an rehabilitation company by 60 million yuan [1]

Core Viewpoint - Xinhua Medical (600587) announced a capital increase of 60 million yuan to its wholly-owned subsidiary, Xinhua Medical Rehabilitation Industry (Xi'an) Co., Ltd., to enhance its operational capacity and development potential [1] Group 1: Company Actions - The company will use its own funds to inject 60 million yuan into the Xi'an Rehabilitation Company to supplement its working capital [1] - This capital increase aims to accelerate the research, production, and sales of rehabilitation equipment [1] Group 2: Company Performance - Xinhua Medical indicated that the Xi'an Rehabilitation Company has made good progress in research and development, production, and sales [1] - The subsidiary has established a solid industrial foundation due to its professional technical accumulation and precise market positioning [1]

证券代码：600587 证券简称：新华医疗 公告编号：临 2026-002 山东新华医疗器械股份有限公司 关于"提质增效重回报"行动方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）为深入 贯彻党的二十大和中央金融工作会议精神，落实国务院《关于进一步提高上市公司 质量的意见》要求，积极响应上海证券交易所《关于开展沪市公司"提质增效重回 报"专项行动的倡议》，践行回报股东的理念，推动公司高质量发展和投资价值提 升，保护投资者尤其是中小投资者合法权益，特制定"提质增效重回报"专项行动 方案，本方案于 2026 年 1 月 4 日经公司第十一届董事会第二十四次会议审议通过， 具体内容如下： 一、聚焦主责主业，加强创新驱动 新华医疗深耕"医疗器械、制药装备"两大制造主业，适度延伸与主业协同的 "医疗服务、医疗商贸"链式发展，以制造业带动发展服务业，服务业促进保障制 造业。双主业布局打造核心业务抢占市场地位。以科技创新为引领，以资本运作为 纽带，加速构建国内国 ...

证券代码：600587 证券简称：新华医疗 公告编号：临 2026-003 山东新华医疗器械股份有限公司 关于对全资子公司新华医疗康复产业（西安）有限公司 增资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 增资标的名称：山东新华医疗器械股份有限公司(以下简称"公司"或"新 华医疗")的全资子公司新华医疗康复产业（西安）有限公司（以下简称"西安 康复公司"）。 增资金额：6,000 万元人民币。 增资实施履行的审批及其他相关程序：公司于 2026 年 1 月 4 日召开 了第十一届董事会第二十四次会议，审议通过了《关于对全资子公司新华医 疗康复产业（西安）有限公司增资的议案》，同意公司使用自有资金向西安康 复公司增资 6,000 万元，用于补充其营运资金，增强其发展能力。本次增资 事项在公司董事会审批范围内，无需提交公司股东会审议。 其它需要提醒投资者重点关注的风险事项：本次增资对象为公司的全 资子公司，整体风险可控，但仍受宏观经济、行业环境、市场竞争、经营管 理等因素的影响，经营状况和收益存在不确定性 ...

证券代码：600587 证券简称：新华医疗 编号：临 2026-001 山东新华医疗器械股份有限公司 第十一届董事会第二十四次会议决议公告 新华医疗康复产业（西安）有限公司（以下简称"西安康复公司"）成立于 2023 年 12 月，注册资本为人民币 2,000 万元，为新华医疗的全资子公司。西安 康复公司主营业务为开展智能康复机器人、康复护理设备、理疗设备等康复产品 研发、制造和销售。 西安康复公司在研发、生产及销售等方面进展良好，凭借专业技术积累和精 准市场定位，已初步建立起良好的产业基础。截至目前，西安康复公司规划产品 项目 24 项，其中 6 个产品项目已经取得注册证；6 个产品项目完成型式检验进 入注册阶段；2 个产品项目完成设计开发验证与确认，进入注册检验测试阶段； 10 个项目完成产品设计，处于样机试制阶段。 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假 记载、误导性陈述或者重大遗漏负连带责任。 一、董事会会议召开情况 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）第十 一届董事会第二十四次会议于 2025 年 12 月 24 日以书面或通讯方式通知全体董 事 ...

证券之星消息，根据天眼查APP-财产线索数据整理，根据内蒙古自治区国际蒙医医院12月28日发布的 《内蒙古自治区国际蒙医医院二期扩建工程彩超、吊塔等医疗设备采购项目政府采购合同公告》内容显 示，山东新华医疗器械股份有限公司中标，详情如下： 标题：内蒙古自治区国际蒙医医院二期扩建工程彩超、吊塔等医疗设备采购项目政府采购合同公告 通过天眼查大数据分析，山东新华医疗器械股份有限公司共对外投资了53家企业，参与招投标项目 11487次；财产线索方面有商标信息211条，专利信息4558条，著作权信息380条；此外企业还拥有行政 许可346个。 采购方：内蒙古自治区国际蒙医医院 供应商：山东新华医疗器械股份有限公司 中标金额：1159000.0 地区：内蒙古自治区 发布日期：2025-12-28 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 数据来源：天眼查APP ...

Group 1: Regulatory Developments - The National Medical Products Administration (NMPA) held a meeting to summarize the regulatory achievements of 2025 and discuss key work for 2026, emphasizing the need for comprehensive regulatory reforms in the cosmetics industry [1] - The meeting highlighted that the Chinese cosmetics market is projected to reach a total transaction value of 1,073.82 billion yuan in 2024, indicating continuous market expansion [1] - Despite the growth, the industry faces structural issues, with over 20,000 registered cosmetics companies but low market concentration and a lack of globally influential brands [1] Group 2: Clinical Innovations and Approvals - The first non-injection epinephrine product, Neffy® (优敏速®), has been approved in China for emergency treatment of severe allergic reactions, marking a significant milestone in drug innovation [4] - HaiXiang Pharmaceutical announced the initiation of Phase II clinical trials for NWRD06, a novel nucleic acid drug aimed at preventing liver cancer recurrence, which is the first of its kind targeting the GPC3 marker [5] - Xinhua Medical received registration for two types of medical devices, enhancing its competitiveness in the in vitro diagnostics market [6] Group 3: Financing and Market Expansion - Beijing Ruifeng Biotechnology completed a C-round financing of over 100 million yuan, aimed at expanding its commercial capabilities and enhancing research and development in both human and animal health [8][9] - Humatrix Medical announced the completion of an A+ round financing of over 100 million yuan, which will be used to advance clinical trials for its core product and expand its product pipeline [10] Group 4: Healthcare Insurance and Spending - The National Healthcare Security Administration reported that from January to November 2025, the total income of the basic medical insurance fund reached 2.632 trillion yuan, with total expenditures of 2.110 trillion yuan, indicating stable fund operations [12]

Group 1 - The company plans to repurchase and cancel a total of 33,370 restricted stocks due to changes in employment status of six incentive recipients, including retirement and job transfers [2][6][7] - The repurchase price is set at 7.55 yuan per share, with interest calculated based on the People's Bank of China's benchmark deposit rate at the time of repurchase [5][6] - Following the cancellation, the company's total share capital will decrease from 606,677,919 shares to 606,644,549 shares [8] Group 2 - The company has received medical device registration certificates for two products: the Interleukin-6 test kit and the Procalcitonin/Interleukin-6 dual test kit, both approved on December 24, 2025 [12][13][16] - The products are designed for quantitative detection of Interleukin-6 and Procalcitonin levels in human blood, plasma, and serum, which are critical in assessing infection severity [15][19] - The introduction of these products enhances the company's competitiveness in the in vitro diagnostic market, providing a variety of options for customers [20]

Key Points - Guizhou Moutai's controlling shareholder, Moutai Group, has completed a share buyback plan, acquiring 2,071,359 shares for a total of 3 billion yuan, increasing its stake to 56.63% of the total share capital [1] - Juneyao Airlines plans to purchase 25 Airbus A320 series aircraft for a total of 4.1 billion USD, with deliveries scheduled between 2028 and 2032 [1] - ST Panda is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws [1] - Huali Co. has terminated its plan to acquire a 51% stake in Zhongke Huilian due to a lack of consensus on key transaction terms [1][2] - China Duty Free Group's subsidiary has signed a contract for a duty-free project at Beijing Capital International Airport, covering an area of 10,646.74 m², with a guaranteed operating fee of 480.27 million yuan in the first year [3] - Haisheng Pharmaceutical's invested company has initiated Phase II clinical trials for NWRD06, a novel RNA drug targeting GPC3 for liver cancer, marking a significant milestone in cancer treatment [3] - WISCO Development is planning to acquire stakes in WISCO Mining and Luzhong Mining through asset swaps and cash payments, leading to a temporary suspension of its stock [4] - Yonghui Supermarket intends to publicly sell a 28.095% stake in its subsidiary Yonghui Cloud Gold Technology [5] - Shanxi Expressway plans to acquire a 15% stake in Shanxi Transportation Industry Development Group for 74.8 million yuan [5] - China Energy Construction's subsidiary has won a 6.864 billion yuan ecological comprehensive governance project [5]